Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7965310

Connective tissue forces from mandibular advancement.

E Ellis·D P Sinn
View original source ↗Export metadata ↓

Abstract

PURPOSE: To quantify the connective tissue forces generated during surgical lengthening of the mandible. PATIENTS AND METHODS: Sixty-three patients who had mandibular advancements by sagittal ramus osteotomy were used in this study. Prior to sectioning the rami, the overjet was recorded. After sectioning the rami, a spring-gauge was attached to the mandibular orthodontic wire and pulled anteriorly to determine how much force was necessary to bring the mandibular incisors into a Class I relationship with the maxillary incisors. Aggressive stripping of the perimandibular periosteum and connective tissues on the distal segment was then performed. The amount of force was again recorded. RESULTS: The mean preoperative overjet in the 63 patients was 6 mm (range, 3 to 11 mm). The mean amount of force required to advance the mandible prior to stripping the tissues was 1,498 g compared with a mean of 787 g after stripping (P < .001). There were statistically significant correlations between the preoperative overjet and the prestripping and poststripping force levels (P < .001). There was also a significant relationship between prestripping and poststripping values (P < .001). CONCLUSION: The results of this study indicate that orthopedic forces are generated by the perimandibular connective tissues following advancement by the mandible. The effect of these forces on the temporomandibular joint should be evaluated in future studies.

Explore related subjects

Bone ResorptionConnective TissueDental Stress AnalysisHumansMalocclusion, Angle Class IIMandibleMandibular CondyleOsteotomyTemporomandibular Joint DisordersJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E Ellis, D P Sinn. 1994. Connective tissue forces from mandibular advancement.. https://doi.org/10.1016/0278-2391(94)90534-7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

The calcium-binding properties of pamidronate, a bone-resorption inhibitor.

The title compound, calcium bis(3-ammonio-1-hydroxypropylidene-1,1-bisphosphonate) dihydrate, Ca(2+).2C(3)H(10)NO(7)P(2)(-).2H(2)O, consists of calcium octahedra arranged in columns along the c axis and coordinated by hydrogen-bonded molecular anions. The Ca(2+) cation lies on a twofold axis. Pamidronate adopts a twisted conformation of the hydroxyalkylamine backbone that enables the formation of an intramolecular N-H...O hydrogen bond. The molecular anion is chelating monodentate as well as bidentate, with an O...O bite distance of 3.0647 (15) A.

Bone Resorption↗
PubMed2002

[Fibrous dysplasia].

The observations in 222 cases of fibrous dysplasia of the Hamburg Bone Tumor Registry will be presented. This benign lesion is based on the appearance of postzygotic point mutations in a gene encoding the Gsa protein. It occurs as a mono- and a polyostotic variant and may affect every bone of the skeleton. Most often affected are the proximal femur, the skull and the ribs. Polyostotic lesions tend to occur on one side of the body. The monostotic form is 7.6 times more frequent, but both variants show no predilection for gender. Most cases are diagnosed during adulthood. On x-rays the lesion has a ground-glass appearance and is located intramedullary with a sharply defined edge. The cortical bone is arroded and the bone is expanded. Histologically typical signs are slender curved fibrous trabeculae with a C and Y shape embedded in a morphologically bland and moderately cellular fibrous stroma. Diagnostically important are collagen fibres emerging perpendicular from the surface of the trabeculae. Cartilage is present in 8% of the cases. Therapeutically, thorough clinical controls are indicated and operative procedures are rarely needed to prevent progressive deformities and fractures. The formerly applied radiotherapy is now obsolete because of the increased occurrence of malignant transformations.

Bone Resorption↗
PubMed2002

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.

PURPOSE: Bisphosphonates have been found to reduce the incidence of skeletal-related events (SREs) in patients with multiple myeloma. This is the first double-blind, randomized, placebo-controlled study to assess the efficacy of ibandronate, a third-generation amino-bisphosphonate, in preventing SREs in advanced-stage multiple myeloma patients. PATIENTS AND METHODS: Patients with multiple myeloma stage II or III were randomly assigned to receive either ibandronate 2 mg or placebo as a monthly intravenous (IV) bolus injection for 12 to 24 months in addition to conventional chemotherapy. SREs such as peripheral pathologic or vertebral fractures, hypercalcemia, severe bone pain, and bone radiotherapy or surgery were analyzed. Bone-turnover markers were also studied. Finally, post hoc analyses of bone morbidity and survival were performed. RESULTS: Ninety-nine patients per treatment group were assessable for efficacy analysis. The occurrence of SRE per patient year and the time to first SRE were not significantly different between the two treatment groups. In overall evaluation, no differences were found between the treatment groups regarding bone pain, analgesic drug use, quality of life, and median survival (33.1 v 28.2 months, respectively). Explorative post hoc analyses revealed that ibandronate patients with strongly suppressed bone-turnover markers (> or = 30% and > or = 50% mean reduction of serum osteocalcin and urinary C-terminal telopeptides) developed significantly less bone morbidity. Ibandronate was tolerated well during as many as 25 therapy cycles. CONCLUSION: Monthly injections of ibandronate 2 mg IV neither reduced bone morbidity nor prolonged survival in the overall population of stage II/III multiple myeloma patients.

Bone Resorption↗